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Abstract 
Idiopathic thrombocytopenic purpura (ITP)
is an acute self-limited bleeding disorder that
can progress to chronic form in 10-15% of the
cases. Helicobacter  pylori (H.  pylori)  infec-
tion is a possible cause of chronic ITP. We
studied 30 children with resistant chronic ITP
for H. pylori infection based on the detection
of H. pylori fecal antigen. This retrospective
study was based on data obtained from med-
ical records of 30 children aged between five
and 17 years (median age at ITP diagnosis
was  ten  years).  A  specially-designed  data
sheet was used to record information on age,
sex,  duration  of  disease,  family  history  of
bleeding disorders, previous treatments and
median  platelet  count.  In  patients  with  H.
pylori infection, antimicrobial treatment con-
sisted  of  amoxicillin,  metronidazol  and
omeprazol.  Response  was  assessed  every
month for one year and defined as complete
(platelet  count  >150×10
9/L)  or  partial
(platelet  count  between  50  and  150×10
9/L).
We detected H. pylori infection in 5 patients.
In  4  of  them  increased  platelet  count  was
seen during one year of follow-up and in one
patient the platelet count was acceptable dur-
ing  six  months.  Although  the  pathological
mechanism of H. pylori-induced thrombocy-
topenia was unclear in our patient sample,
the assessment of H. pylori infection and use
of eradication therapy should be attempted in
chronic and resistant ITP patients.
Introduction
Helicobacter is a genus of gram-negative
bacteria causing peptic ulcer, chronic gastri-
tis and lymphoma.
1 There is a suggestion that
H. pylori has a role in the pathogenesis of
chronic idiopathic thrombocytopenic purpura
(ITP).
2 However, the relationship between H.
pylori infection and cITP is less clear. In chil-
dren, eradication of the infection was report-
ed to produce an increase in platelet count in
one study,
3 whereas another report failed to
demonstrate this beneficial effect.
4 In adults,
the  connection  between  H.  pylori infection
and ITP is also controversial.
5,6
In the light of this controversy, we designed
the present study to evaluate the role of H.
pylori in patients with chronic and resistant
forms of ITP and the effect of H. pylori eradi-
cation on platelet count in these patients.
Materials and Methods
This retrospective study involved 30 chil-
dren with chronic ITP younger than 18 years
of age referred consecutively to the Motahari
Outpatient  Pediatric  Clinic  of  Shiraz
University of Medical Science, during 2003 to
2006.  The  research  itself  lasted  14  months
(from 2006 to 2007) and was approved by the
Medical  Ethics  Committee  of  Shiraz
University of Medical Sciences (Table 1).
The median age at ITP diagnosis was ten
years (range, 5-17 years). The inclusion crite-
ria were thrombocytopenia of more than six
months’  duration  (chronic  ITP),  lack  of
response to multidrug treatment with corti-
costeroids,  intravenous  immunoglobulin,
RhoGAM  (anti-D  immunoglobulin)  and
splenectomy (for resistant forms of ITP), and
platelet count below 100×10
9/L (Table 1). We
used a specially designed data sheet to record
information on age, sex, duration of the dis-
ease, median platelet count, type of  previous
treatment, and family history of autoimmune
disorder.  Stool  samples  were  tested  for  H.
pylori antigen  with  an  enzyme-linked
immunosorbent assay (ELISA) kit (Meridian
BioScience, Cincinnati, OH, USA). In patients
with H. pylori antigen an eradication regimen
was  given  as  follows:  1)  omeprazol 
1 mg/kg/day for four weeks, 2) metronidazol
30 mg/kg/day for two weeks, and 3) amoxi-
cillin 60 mg/kg/day for two weeks.
Platelet recovery occurred one month after
H. pylori eradication, which was confirmed by
the disappearance of H. pylori antigen from
stool.  Subsequently,  platelet  count  was
checked every month for one year and com-
pared with the patient’s median platelet count
before H. pylori eradication. 
During  the  follow-up  period,  patients  did
not  receive  any  medication.  Response  was
defined  as  complete  (platelet  count
>150×10
9/L)  or  partial  (platelet  count
between 100 and 150×10
9/L ), and relapse was
defined as a decrease in platelet count to pre-
treatment values. 
Two statistical methods (paired t-test and
Wilcoxon’s  signed  rank  test)  were  used  to
analyze the results. p less than 0.05 were con-
sidered statistically significant.
Results
We  detected  5  H.  pylori-positive  cases
according to the presence of the antigen in
stool. None of the patients complained of gas-
trointestinal  problems.  The  prevalence  of  H.
pylori infection in patients with chronic ITP
was 16.6%.  
After  H.  pylori was  eradicated  in  patients
with  the  infection,  platelet  count  was
rechecked monthly for one year (Table 2).
Median platelet count in our patients during
one  year  after  treatment  increased  from
18.6×10
9/L to  79.2×10
9/L with  a  p of  0.043
(Wilcoxon’s  signed  rank  test)  and  0.001
(paired t-test). According to the definition of
partial response (platelet count between 50-
150×10
9/L)  our  data  showed  an  increase  in
platelet count in our patients in this category.
In 4 patients, platelet count remained constant
during  one  year  of  follow-up,  and  in  one
patient it remained stable for six months and
then  decreased  to  its  pre-treatment  value
(Table 3). At this time this patient showed evi-
dence of re-infection in the fecal antigen test.
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By  repeating  H.  pylori eradication,  the
patient’s platelet count increased one month
after treatment, and remained stable during
follow-up. None of the other 4 patients showed
evidence of H. pyloriinfection after one year of
follow-up.  In  the  H.  pylori-negative  group,
platelet  count  was  checked  monthly  for  one
year but did not increase spontaneously.
Discussion
In  1998,  Gasbarrini  et  al.
2 first  reported
improvements in platelet count after H. pylori
eradication in adults with chronic ITP. Several
studies  have  shown  that  platelet  count  in
patients with ITP returns to normal after erad-
ication.
7,8 Although the investigation and erad-
ication of H. pylori infection in children with
chronic ITP is a matter of debate, there are few
reports about children with this disease.
9-12
Although  the  association  between  the
pathogenesis of ITP and H. pylori is still not
well defined, the search for H. pylori infection
and  attempts  to  eradicate  the  bacterium  in
positive  cases  seem  appropriate  in  adult
patients  as  well  as  children.  Some  authors
reported  that  the  pre-treatment  factor  most
consistently associated with platelet response
to H. pylori eradication was shorter ITP dura-
tion,
13,14 but  our  study  did  not  confirm  this.
Others have also suggested that patients with
very low platelet counts appear to have fewer
chances of responding, but we obtained a bet-
ter response in this group. Torres et al.
15 found
that  H.  pylori positivity  was  higher  in  older
children, but we found no significant differ-
ences in this parameter between children of
different ages. This may be due to earlier H.
pylori infection in our country.
16
The rate of positivity for H. pylori infection
was lower in our series (16.6%) compared to
the  Italian  pediatric  population,  in  which  a
prevalence  of  22-28%  was  found.
17,18 Other
characteristics such as age, sex, and previous
therapies,  including  corticosteroids  and
splenectomy,  were  not  useful  in  predicting
platelet  response.  Our  results  indicate  that
eradication of H. pylori is accompanied by a
platelet response in some ITP patients, with
ample variations in the response rate among
different  series.  Bacterial  factors  (i.e.,  the
variability of H. pylori strains) may account for
these findings. In this connection, Emilia et
al.
8 reported a response rate of 50% whereas
we obtained a response rate of 100%, which
was consistent with the findings of Gasbarrini
et al.
2 It seems that H. pylori eradication is
greatly favorable to standard ITP therapy due to
low  cost,  its  non-invasive  nature  and  much
less toxicity. So H. pylori infection eradication
should be considered in those patients with
chronic and resistant ITP.
19
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